Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis

Rechallenge of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) after PD-1 blockade failure was an effective therapy for non-small cell lung cancer (NSCLC) patients with resistance to EGFR-TKIs. The third-generation TKIs, like osimertinib and furmonertinib, can reach higher co...

Full description

Bibliographic Details
Main Authors: Chunfa Qian, Yuhai Zhang, Wanwan Cheng, Qingchao Zhang, Mengzhen Li, Shencun Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
lung adenocarcinoma
EGFR-TKIs rechallenge
immune checkpoint inhibitor
the third generation EGFR-TKIs
leptomeningeal metastasis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.957661/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.957661/full

Similar Items